GLP1R and obesity disorder: Retatrutide – a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors – at a dose of 12 mg for 48 weeks has been recently associated with a remarkable 24.2% weight loss in adults with obesity (7).